Telaprevir to boceprevir switch highlights lack of cross-reactivity.

Abstract excerpt

Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cross Reactions
• Share to Drug Substitution
• Share to Eosinophilia